Evidence map›Paper›PMID 33868719›Full record

ArticleJournal of translational science2021

Differential effects of minocycline on microvascular complications in murine models of type 1 and type 2 diabetes.

Stephanie A Eid, Phillipe D O'Brien, Lucy M Hinder, John M Hayes, Faye E Mendelson, Hongyu Zhang, Samanthi Narayanan, Steven F Abcouwer, Frank C Brosius, Subramaniam Pennathur and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Journal of translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 7 citations in OpenAlex.

  1. NONcNZO10/LtJ and TALLY-HO/JngJ Mice as Novel Models of Diabetic Peripheral Neuropathy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Diabetic Neuropathy of the Retina and Inflammation: Perspectives.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Neurovascular Impairment and Therapeutic Strategies in Diabetic Retinopathy.International journal of environmental research and public health · 2021
    Review
  8. Commentary: Oral management of diabetic retinopathy.Indian journal of ophthalmology · 2021
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Stephanie A EidDepartment of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.
Phillipe D O'BrienDepartment of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.
Lucy M HinderDepartment of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.
John M HayesDepartment of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.
Faye E MendelsonDepartment of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.
Hongyu ZhangDivision of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, U.S.A.
Samanthi NarayananDepartment of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.
Steven F AbcouwerDepartment of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, 48105, U.S.A.
Frank C BrosiusDivision of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, U.S.A.
Subramaniam PennathurDivision of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, U.S.A.
Masha G SavelieffDepartment of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.
Eva L FeldmanDepartment of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.
University of Michigan–Ann Arbor · US

Funding

Pilot and Feasibility (P and F) ProgramP30DK089503 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Kanakadurga Singer · 2010 to 2026
$20.3M
VIVARIUM MODULEP30EY007003 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David Antonetti · 1987 to 2026
$17.6M
Integrated Systems Biology Approach to Diabetic Microvascular ComplicationsR24DK082841 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ABCOUWER, STEVEN F, BROSIUS, FRANK C · 2008 to 2020
$13.1M
University of Michigan O'Brien Kidney Translational Core CenterP30DK081943 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BROSIUS, FRANK C · 2008 to 2022
$12.9M
LIPID, LIPOPROTEIN, AND GLUCOSE METABOLISM COREU24DK059630 · NIDDK · UNIVERSITY OF CINCINNATI · PI TSO, PATRICK · 2001 to 2015
$12.9M
Michigan Mouse Metabolic Phenotyping CenterU2CDK110768 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ELIAS, CAROL FUZETI · 2016 to 2021
$6.2M
Molecular Regulation of Photoreceptor Cell DeathR01EY020823 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ABCOUWER, STEVEN F, ZACKS, DAVID N · 2010 to 2023
$5.0M
Lipid profile, lipoprotein and apolipoprotein composition, and intestinal fat absorption efficiency in germ-free and conventional miceU2CDK059630 · NIDDK · UNIVERSITY OF CINCINNATI · PI LIU, MIN · 2016 to 2021
$4.9M
Regulation of Retinal Cell Death in DiabetesR01EY020582 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ABCOUWER, STEVEN F, GARDNER, THOMAS W. · 2010 to 2018
$4.0M
Inflammatory Resolution and Vascular Restoration in Diabetic RetinopathyR01EY029349 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ABCOUWER, STEVEN F, ANTONETTI, DAVID · 2018 to 2022
$2.4M
Linking Nerve Bioenergetics with Metabolomics: New Insights into Diabetic NeuroapthyR21NS102924 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FELDMAN, EVA LUCILLE · 2018 to 2019
$429k
NEI NIH HHS P30 EY007003NEI NIH HHS R01 EY020582NEI NIH HHS R01 EY020823NEI NIH HHS R01 EY029349NIDDK NIH HHS P30 DK081943NIDDK NIH HHS P30 DK089503NIDDK NIH HHS R24 DK082841NIDDK NIH HHS U24 DK059630NIDDK NIH HHS U2C DK059630NIDDK NIH HHS U2C DK110768NINDS NIH HHS R21 NS102924
6 · The paper itself

Abstract

Diabetes is a global healthcare problem associated with enormous healthcare and personal costs. Despite glucose lowering agents that control glycaemia, both type 1 (T1D) and type (T2D) diabetes patients often develop microvascular complications that increase morbidity and mortality. Current interventions rely on careful glycemic control and healthy lifestyle choices, but these are ineffective at reversing or completely preventing the major microvascular complications, diabetic peripheral neuropathy (DPN), diabetic retinopathy (DR), and diabetic kidney disease (DKD). Minocycline, a tetracycline antibiotic with anti-inflammatory and anti-apoptotic properties, has been proposed as a protective agent in diabetes. However, there are no reported studies evaluating the therapeutic efficacy of minocycline in T1D and T2D models for all microvascular complications (DPN, DR, and DKD). Therefore, we performed metabolic profiling in streptozotocin-induced T1D and db/db T2D models and compared the efficacy of minocycline in preventing complications to that of insulin and pioglitazone in both models. Minocycline partially ameliorated DR and DKD in T1D and T2D animals, but was less effective than insulin or pioglitazone, and failed to improve DPN in either model. These results suggest that minocycline is unlikely to improve outcomes beyond that achieved with current available therapies in patients with T1D or T2D associated microvascular complications.

Indexed as

diabetesminocyclinenephropathyperipheral neuropathyretinopathy

Identifiers

PMID33868719
PMCPMC8048053
OpenAlexW3127874994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.